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Current diagnostic tests for typhoid fever, the disease caused by Salmonella Typhi, are
poor. We aimed to identify serodiagnostic signatures of typhoid fever by assessing
microarray signals to 4,445 S. Typhi antigens in sera from 41 participants challenged
with oral S. Typhi. We found broad, heterogeneous antibody responses with increasing
IgM/IgA signals at diagnosis. In down-selected 250-antigen arrays we validated
responses in a second challenge cohort (n = 30), and selected diagnostic signatures
using machine learning and multivariable modeling. In four models containing responses
to antigens including flagellin, OmpA, HlyE, sipC, and LPS, multi-antigen signatures
discriminated typhoid (n = 100) from other febrile bacteremia (n = 52) in Nepal. These
models contained combinatorial IgM, IgA, and IgG responses to 5 antigens (ROC AUC,
0.67 and 0.71) or 3 antigens (0.87), although IgA responses to LPS also performed
well (0.88). Using a novel systematic approach we have identified and validated optimal
serological diagnostic signatures of typhoid fever.
Keywords: Salmonella Typhi, serodiagnostics, antibody response, fever diagnostics, enteric fever, machine
learning, controlled human infection model, rapid diagnostic tests
INTRODUCTION
Typhoid fever is a febrile illness common in tropical regions of South and Southeast Asia, and is
becoming increasingly recognized in sub-Saharan Africa (Crump et al., 2015; Wain et al., 2015).
The causative bacterium Salmonella enterica serovar Typhi (S. Typhi) is transmitted between
humans by the faeco-oral route, and is associated with 12 to 27 million illnesses each year (Crump
et al., 2004; Buckle et al., 2012; Mogasale et al., 2014). Estimates of typhoid disease burden are
broad and likely inaccurate due to lack of systematic studies and inadequate diagnostic methods
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(Crump et al., 2008; Crump, 2014; John et al., 2016). Management
of individual cases may also be similarly compromised; whereas
rapid diagnostic tests (RDTs) have been developed for other
common tropical febrile infections, no such tests currently exist
for typhoid (Baker et al., 2010; Parry et al., 2011; Andrews and
Ryan, 2015).
The diagnosis of typhoid fever is dependent on traditional
microbiological techniques and clinical judgment (World Health
Organisation, 2003), with blood culture still considered to be the
gold-standard. While modern blood culture facilities may achieve
a diagnostic sensitivity of 80% and a specificity approaching
100% (Mogasale et al., 2014; Waddington et al., 2014),
sensitivity is often compromised due to a low concentration
of organisms in the blood on clinical presentation and the
use of antimicrobials before hospitalization (Wain et al., 1998;
World Health Organisation, 2003). The classic serological
method for diagnosing typhoid fever is the Widal test, which
measures agglutination of serum antibodies against S. Typhi
flagellin and lipopolysaccharide (LPS) (Crump et al., 2015).
The useful application of the Widal test is complicated in
endemic settings, however, due to cross-reactivity with other
antigens and the need for either paired samples or population-
specific baseline samples (Baker et al., 2010; Keddy et al.,
2011). As a result of the low blood volume requirements
and possible extrapolation to using non-blood clinical samples,
serological responses remain an appealing approach for typhoid
diagnostics, although a central shortfall has been a lack of
diagnostic antigen candidates for S. Typhi (Darton et al.,
2014).
We previously established a controlled human infection
model (CHIM) of typhoid fever (Waddington et al., 2014;
Darton et al., 2016). This model readily lends itself to the
interrogation of immune responses after an oral challenge
with virulent S. Typhi. In tandem, the fabrication of a pan-
Salmonella proteome array by antigen expression using a coupled
Escherichia coli-based in vitro transcription and translation
(IVTT) system has enabled the systematic assessment of
humoral antibody responses to vaccination and/or infection
(Davies et al., 2005; Liang and Felgner, 2015). Here, we
describe an assessment of the humoral immune response
after oral challenge with virulent S. Typhi, through infection
and into convalescence. We aimed to identify and validate
novel signatures of antigen/antibody isotype combinations using
typhoid CHIMs, before evaluating the performance of these
diagnostic signatures in febrile patients in a typhoid-endemic
area of Nepal.
RESULTS
Discovery of a Diagnostic Signature in a
Typhoid CHIM
Arrays consisting of 4,445 S. Typhi antigens expressed using
IVTT plus purified S. Typhi LPS and flagellin were used
to probe sera collected from 41 participants challenged
with S. Typhi (Figure 1A and Table 1) (Waddington
et al., 2014; Darton et al., 2016). We measured IgA,
IgM, and IgG reactivity in all individuals up to day 28
after challenge (Figure 1A and Supplementary Figure S1).
All participants diagnosed with typhoid fever (TD)
developed humoral responses; these responses were
heterogeneous with few antigens represented across all
samples (Figure 2). Moreover, TD participants exhibited a
broader range of antibody responses for all three isotypes
than participants not developing infection (nTD) after
challenge.
Antigen/isotype combinations reaching predetermined
reactivity criteria (fold-change >1.5 from baseline in >2
participants) at day 14 in all participants plus the 96 h after
TD (TD96 h) time point in TD participants, according to
the outcome after challenge, included flagellar components,
HlyE, lipoproteins, regulatory proteins, OmpA and others
distributed between all three isotypes (7 IgA, 8 IgG, and 16
IgM antigens; Supplementary Table S1). These data reconfirmed
the heterogeneity in responses by TD participants, particularly
at early time points (Figure 3 and Supplementary Figures
S2A–C). In contrast, sera from nTD participants exhibited
little reactivity to these same antigens (Supplementary
Figures S2D–F, S3).
Validation of Selected Antigen/Antibody
Isotypes
Using the discovery set data and previously published data
(Lee et al., 2012; Liang et al., 2013; Davies et al., 2016),
we produced a down-selected array consisting of 223
S. Typhi, 6 dengue virus, and 11 Plasmodium falciparum
antigens and purified S. Typhi antigens, Vi, LPS and flagellin
(Supplementary Methods and Table S2). The resulting arrays
were probed with sera from an independent cohort of S. Typhi
challenged participants (validation set, n = 30) to verify the
results from the discovery cohort (Figure 1B) (Darton et al.,
2016).
Of the 31 antigen/antibody isotype combinations selected
from the discovery set, six had significant increases in sera
reactivity at the TD96 h time point in those diagnosed with
typhoid (paired t-test) and nine had significant increases in
sera reactivity at the day 14 time point (Figure 4). We
observed significant responses to four antigens per isotype:
IgG and IgA with HlyE and OmpA, IgG, and IgM with
flagellin and the flagellar hook protein E (FlgE). Unique
antigen/antibody isotype signals were observed with IgM against
a putative N-acetylmuramoyl-L-alanine amidase (t2002) and an
uncharacterised protein (t2295), and with IgG against methyl
viologen resistance protein SmvA (t1485) and bifunctional
protein Aas (t2919).
To further explore the diagnostic potential of the
antigen/antibody isotype combinations selected from the
discovery set, we plotted receiver operator characteristic
(ROC) curves for each combination; we used the fold-change
between day 14 and baseline to discriminate all challenge
study participants reaching a study diagnosis of typhoid from
those who did not (Supplementary Figure S4). These analyses
confirmed the discriminative ability of IgA and IgG isotype
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FIGURE 1 | Structure of the controlled human infection models of typhoid fever and endemic cohort. In both (A) the discovery set and (B) the validation set, study
participants ingested 103–104 CFU Salmonella Typhi Quailes strain suspended in oral sodium bicarbonate solution on day 0 (D0). Sera samples were collected and
probed at the time points indicated. Participants developing an oral temperature ≥38◦C sustained for ≥12 h or evidence of bacteremia after challenge were
diagnosed with typhoid (TD) and commenced on antimicrobial treatment. All remaining participants not diagnosed during the 14-day period (nTD) were commenced
on the same treatment on day 14. (C) Samples (serum and blood culture) in the endemic setting cohorts were collected on one occasion at point of hospital
presentation. Pathogens isolated from blood cultures collected from other, non-S. Typhi bacteraemia cases are listed in the box.
responses to HlyE (t1477) and OmpA (t1850) based on their high
AUC values (>0.75); the IgM responses were less discriminatory.
Selection of Antigen/Isotype
Combination Signatures by Machine
Learning
While the initial analysis identified a set of antigens to evaluate
in a multivariable model, we further aimed to optimize antigen
selection using complementary, data driven approaches to down-
select antigen/antibody isotype combinations using machine
learning algorithms. To achieve reasonably sized training and test
sets and to maximize the available data points included, we used
both discovery and validation sets (n= 71) and antigen/antibody
isotype combinations common to the full and down-selected
arrays to form one large data matrix (‘superset’) consisting of 715
features (Supplementary Methods).
A principal component analysis (PCA) of all antigens
common to the challenge and Nepal datasets indicated
substantial response homogeneity (Supplementary Figure S5);
with the exception of two Nepal samples that were excluded
from subsequent analyses. We initially tested four different
algorithms: partial least squares regression (PLS) (Mevik and
Wehrens, 2007), nearest shrunken centroid classification (NSC
or PAM) (Tibshirani et al., 2002), radial and linear support vector
machines (SVMs) (Karatzoglou et al., 2004).
Overall, radial SVM was the algorithm with the lowest
predictive accuracy according to AUROC scores, and the lowest
balance accuracy (Figure 5A). The NSC method produced high
predictive accuracies but only performed well with large classifier
sets and thus both methods were excluded from subsequent
analyses (Figure 5A and Supplementary Figure S6). Due to the
performance of the PLS regression and overlap seen with the
linear SVM algorithm (Supplementary Figure S7), subsequent
analyses were performed using antigens selected by the PLS
method only. Mapping the overall selection frequency of specific
antigens selected by the PLS model indicated that OmpA (t1850),
putative membrane protein (t3090), HlyE (t1477), putative
N-acetylmuramoyl-L-alanine amidase (t2002) and FlgE (t1743)
were selected in>80% of the classifiers built by the PLS algorithm
(Figure 5B). Using a threshold of >10% selection frequency
across all 500 iterations, 35 unique antigen/antibody isotype
combinations were selected as candidates for multivariable
modeling (Figure 5C and Supplementary Table S3).
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TABLE 1 | Demographics.
Study Discovery cohort Validation cohort Endemic cohort
Identifier OVG2009/10 OVG2011/02 NA
Location Oxford, United Kingdom Oxford, United Kingdom Kathmandu, Nepal
Source S. Typhi Quailes strain
dose-escalation study
(103 and 104CFU)
(Waddington et al., 2014)
Placebo arm of randomized
controlled vaccine/challenge
trial (Darton et al., 2016)
Treatment trial and diagnostics
sub-study (Arjyal et al., 2016;
Darton et al., 2016)
Trial registration NA Clinicaltrials.gov
(NCT01405521)
Clinicaltrials.gov
(NCT01421693)
Sample size, N 41 30 202
Confirmed casesA, n (%
bacteremia)
25 (84) 20 (100) 100 (100)
Exposed, not sickB, n 16 10 NA
Healthy controlsC, n 41 30 50
Febrile non-typhoid bacteremia, n NA NA 52D
Median age, yrs (interquartile range) 27 (22–37) 23 (21–39) 20 (15–27)E,F
Number male (%) 28 (68) 19 (63) 99 (49)E,G
NA, not applicable. CFU, colony-forming units.
ACase confirmation in the challenge studies was made using clinical (oral temperature 338◦C sustained for 312 h continuously) or microbiological (S. Typhi bacteraemia
detected in 31 blood culture sample). All confirmed cases in the endemic cohort were confirmed to have bacteremia.
BCHIM study participants who ingested challenge agent and were monitored for 14 days but did not meet the endpoints for typhoid diagnosis (see A, above).
CHealthy controls in the challenge study were paired pre-challenge samples from the same individual.
DPathogens isolated (n) were: Staphylococcus aureus (20), Escherichia coli (16), Streptococcus pneumoniae (6), Enterococcus sp. (5), Acinetobacter sp. (3),
Streptococcus sp. (1), Klebsiella sp. (1).
EMissing data = 6/202 healthy controls.
FTyphoid patients, 16 (10–20); Healthy controls, 22.5 (19–26.25); Febrile controls, 40 (22–56.75).
GTyphoid patients, 67 (67%); Healthy controls, 11 (22%); Febrile controls, 21 (40%).
Confirmation of Antigen/Antibody
Isotype Signature
To identify a combination of a small number of antigen/antibody
isotypes that were predictive of typhoid challenge outcomes
(TD or nTD) in a multivariable framework, we performed
multivariable logistic regression. Many of the 35 selected
antigen/antibody isotype combinations identified in the
PLS regression were highly correlated with each other
(Supplementary Figure S8A). Due to the intrinsic problems
of model overfitting and model non-convergence, the 35
candidate antigen/antibody isotypes were further reduced prior
to model fitting by removing those antigen/isotype combinations
with the lowest frequency of selection (<30%) and combinations
which consisted of two isotypes of the same antigen and were
therefore highly correlated (correlation cut-off rho > 0.7;
Supplementary Figure S8B and Supplementary Methods).
This process resulted in 12 candidate antigen/antibody isotype
combinations/features (Figure 6A). To identify the optimal
feature combination we applied logistic regression to these 12
variables using step-wise back and forward feature selection
(based on AIC statistics). This analysis resulted in a final
model consisting of five antigen/antibody isotype combinations
(Table 2 and Figure 6A – gray squares; Model 1). Individual risk
scores were calculated from the linear predictor of the logistic
regression, i.e., the sum of the fold-change values multiplied
by variable coefficients for each participant (Figure 6B). The
bias inherent in internal validation was observed, with very
high sensitivity and specificity for correctly assigning challenge
outcome (AUC ROC = 0.955) seen when the model was fitted to
the data from which it had been derived (Figure 6C). External
validation on the Nepal dataset was conducted to obtain an
objective estimate of the model performance in an endemic
setting.
IgM for putative membrane protein (t3090) was not selected
in the model, likely due to its positive correlation with multiple
variables. Since responses to t3090 were some of the strongest
observed in both the Oxford validation and Nepal datasets
(Figures 6A,D), we repeated the analysis forcing IgM t3090 to
be kept in the model. This process resulted in a slightly modified
antigen combination, which excluded IgM t2002 (putative
N-acetylmuramoyl-L-alanine amidase) (Table 2 and Figure 6A –
black squares; Model 2) but had little effect on risk scores
or ROC curve analysis in internal validation (AUC = 0.953;
Figures 6B,C).
Inclusion of Purified Proteins
Reactivity against purified antigens (LPS, flagellin, and Vi)
was substantial in all three cohorts at the selected time
points - Vi polysaccharide was not printed on the initial
array, which was used for probing sera in the discovery
set (Supplementary Figure S9). IgA responses to flagellin
and LPS were highly correlated (rho = 0.625) with each
other and other antigens in the dataset, in particular OmpA
(t1850), flagellin (t0918), flagellar hook protein E (t1743),
regulatory protein (t3426) and N-acetylmuramoyl-L-alanine
amidase (t2002) (Supplementary Figure S8B). Model selection
was performed with LPS forced into the model (model 3, Table 2),
and additionally, a model with LPS alone was assessed (Model
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FIGURE 2 | Reactivity of 4445 antigens in samples from a human challenge study performed in Oxford (Discovery set). (A) Mean number of creactive antigen per
participant at time points D0 – D28 following challenge. Blue: nTD group. Red: TD group. Gray shaded area: acute disease (TD48 and TD96 h). (B) Number of
reactive antigens in number of samples at TD+96 h, and D14 for both groups.
4, Table 2). When LPS was forced into the model, the final
model included the additional antigens IgA.t2786 and IgG.t1477
(Figures 6A–C).
Assessment in an Endemic Cohort
Using the down-selected antigen array, we probed sera samples
gathered from cohorts of patients in Nepal with blood culture-
confirmed typhoid fever (n = 100; ST), patients with confirmed
non-typhoid bacteremia (n = 52; febrile controls, FC) and
healthy controls (n = 50; HC), to assess the performance of
antigen/antibody isotype signatures identified (Table 1). The
resulting data were heterogeneous with no apparent clustering
between the healthy controls, febrile controls and typhoid
patients, although more consistent clustering was observed
among different isotypes (Supplementary Figure S10). The
differences between typhoid samples and healthy controls for
the 12 antigen/antibody isotypes used in the multivariable
analysis were less pronounced in the Nepal cohort. For some
antigens, the values for febrile controls were decreased when
compared with healthy controls. The most distinct responses
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FIGURE 3 | Time course of responses to four selected antigen/antibody isotype combinations by participants challenged and subsequently diagnosed with typhoid
fever. (A) IgA responses. (B) IgG responses. (C) IgM responses. (D) Responses to purified S. Typhi flagellin (0.1 µg) and lipopolysaccharide (LPS, 0.1 µg) as
additional antigens included on the array. Vertical black dashed line, TD time point; vertical green dashed line, TD+48hr time point; vertical blue dashed line, TD+96hr
time point.
were observed for IgM.t3090 and IgA/IgG LPS (Figure 6D). This
observation was further reflected in the risk score analysis, with
moderate differences between the febrile controls and typhoid
cases (Figure 6E).
Model 1 with 5 antigens and model 2 with t3090 forced
into the model showed moderate discrimination between
blood culture positive typhoid participants and febrile controls,
while models containing LPS or LPS alone performed better
(Figure 6F). A comparison of AUCs by DeLong’s test for two
correlated ROC curves, showed significant differences between
the performance of each of model 2, model 3 and model 4, with
model 1 (p = 0.017, p = 8.8 × 10−6, and p = 6.2 × 10−6,
respectively; Table 3).
DISCUSSION
Here we have detailed the entire breadth of the humoral response
during acute typhoid fever using a comprehensive S. Typhi
proteome array. Using samples collected in human challenge
studies and an endemic setting enabled systematic identification
and validation of panels of candidate diagnostic antigen/antibody
isotype signatures for typhoid fever. Putative serodiagnostic
antigens identified include components of the bacterial cell
surface and proteins targeted toward host cell attack (HlyE) and
invasion (SipC).
Successful application of antigen microarray technology to
identification of candidate diagnostic or vaccine targets has been
used for multiple pathogens (Liang et al., 2011a,b; Kalantari-
Dehaghi et al., 2012; Liang and Felgner, 2015), but this technology
has not yet been widely applied to S. Typhi (Bumann, 2014).
A key reason may be the challenge in obtaining samples
from human patients with confirmed typhoid fever in a high-
incidence setting. Furthermore, interpreting the significance of
seroreactivity in samples collected in an endemic setting is
problematic as previous exposure or subclinical infection by
typhoidal or non-typhoidal Salmonella is difficult to exclude.
Our approach was to use samples collected during human
challenge studies, thus developing a ‘cleaner’ route for antigen
discovery, effectively removing the background cross-reactive
antibody response (Liang et al., 2013; Davies et al., 2016).
An assessment of the challenge study samples highlighted the
marked heterogeneity observed in humoral responses occurring
during typhoid fever and showed negligible responses in those
not succumbing to overt clinical infection, despite exposure.
Explanations for response heterogeneity include the complex
host-pathogen interactions governed by bacterial subversion
and immunomodulation, bacterial burden and variability in the
magnitude of the host immune response (Wain et al., 1998;
Dougan and Baker, 2014; Waddington et al., 2014).
We aimed to address variability in serological response by
seeking a signature consisting of multiple antigens/antibody
isotypes, rather than relying solely on a single antigen. This
approach was in-keeping with the previous work by Liang et al.
(2013) who identified a signature composed of either IgM or
IgG responses against 10 antigens performed better than those
containing fewer antigens. We applied various computational
methods for selecting optimal combinations of antigen/isotype
pairs as diagnostic markers. Several of the identified antigens
corroborate previous findings while others are novel targets.
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FIGURE 4 | Reactivity and diagnostic performance of antigen/antibody isotype combinations selected from the discovery set and applied to the validation set.
Antigen names are given in Supplementary Table S1. Boxplots of fold-change in reactivity between TD+96hr and day 14 time points in TD or day 14 in nTD
participants and individual baseline FI values, to antigen/antibody isotype combinations selected from the discovery set. Paired t-tests were performed between the
time point featured and baseline values. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
The IgA and IgG responses to HlyE (t1477) were identified in
previous typhoid microarray studies for distinguishing typhoid
from controls and other febrile infections including NTS (Liang
et al., 2013; Charles et al., 2014; Davies et al., 2016). Furthermore,
diagnostic HlyE responses have been further validated by other
laboratory techniques including ELISA (Charles et al., 2010,
2014), and dot-blot immunostrip probing (Liang et al., 2013;
Davies et al., 2016). We additionally identified IgA and IgG
responses to OmpA (t1850) as seroreactive in our CHIM
participants. IgG responses to OmpA were classed by Liang
et al. (2013) as cross-reactive, and were also identified in both
acute and convalescent sera samples using an immunoproteomic
screening assay in Bangladesh (Charles et al., 2014). Other
Salmonella and Gram-negative bacteria express OmpA; therefore
this antigen may not be useful in settings where background
exposure is common. In the non-endemic challenge population
the OmpA response was a useful discriminator for infection. Of
note, comparative IgM/IgA responses to S. Typhi-specific OMP
form the basis of the Typhidot-M test, which has been shown
to distinguish typhoid infection in febrile children in Malaysia
(Choo et al., 1999), but performs less well in other settings
(Naheed et al., 2008; Fadeel et al., 2011; Keddy et al., 2011;
Thriemer et al., 2013; Islam et al., 2016).
Flagellin has long been recognized as a potential diagnostic
antigen (Calderon et al., 1986; Sadallah et al., 1990), and is a
component of the Widal test (Parry et al., 2011). We detected
responses to flagellin [both as the IVTT expressed antigen
(t0918) and in purified form on the array] by all three isotypes,
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FIGURE 5 | Selection of an antigen/antibody isotype signature using machine learning algorithms applied to the controlled human infection typhoid datasets.
(A) Test set prediction performance measures AUC receiver operator characteristic (ROC) and balanced accuracies (BalAcc) for four different machine learning
models using 500 bootstrap samples of the data. (B) Frequency of features selected in each of 500 iterations by the partial least squares (PLS) algorithm.
(C) Proportions of features selected across all 500 bootstrap samples using the PLS algorithm. Features had to be selected in at least 10% of the bootstrap samples
(column ‘overall’). Proportions are split by classifier size. The last column represents the overall proportion across all 500 bootstrap samples.
suggesting flagellin as a useful serodiagnostic classifier in the non-
endemic discovery and validation cohorts. While flagellin was
selected through machine learning, it was not a component of
any identified signatures and correlated with responses against
O-antigen. Responses against flagellin appeared to be short-
lived after infection, and were not observed in all diagnosed
individuals. This apparent difference in systemic exposure may
account for the failure of many flagellin-based PCR assays to
improve on the sensitivity of current diagnostic methods when
tested with clinical samples (Tennant et al., 2015; Darton et al.,
2017). Similarly, IgG and IgM responses to flagellar hook protein
E (FlgE, t1743) were also significantly more reactive in TD
participants in the CHIM. This structure is closely related to
flagellin (Homma et al., 1990), and is likewise probably similarly
cross-reactive when seen (Liang et al., 2013).
Two IgM responses to entirely novel antigen candidates were
identified as being serodiagnostic in the challenge participants.
These included a putative N-acetylmuramoyl-L-alanine amidase
(t2002, STY0927), which is involved in the catabolism of
peptidoglycans and has previously been associated with the
invasion and intracellular survival of Salmonella Typhimurium
(Folkesson et al., 2005). Also identified was an uncharacterized
hypothetical protein, t2295. While wide ranging cross-reactivity
was observed with the IgM responses, reactivity to these two
antigens performed well even in the machine learning selection,
with IgM against t2002 taken forward into one of the diagnostic
signatures (Model 1). Multivariable analysis identified two
further previously unknown antigens as part of the signature
determined in Model 2. These included IgM responses to YjeN
(t4398), a previously uncharacterized protein, and IgG responses
to a glycerol-3-phosphate transporter (t0581, STY2512).
During machine learning analysis of the CHIM validation
dataset, additional IgM responses to t3090 (a putative membrane
protein) were identified as demonstrating diagnostic merit;
these responses were also markedly increased in the Nepal
dataset. This result was unpredicted; as previous exposure to
Salmonella antigens would indicate that IgM responses might
be less likely to predominate in an endemic setting. Therefore,
we formed an additional multivariable model, forcing selection
of IgM.t3090 (Model 2). Inclusion of this combination into the
model altered signature composition slightly (with removal of
IgM.t2002) but interestingly resulted in a significantly improved
test performance when applied to the Nepal dataset (higher AUC
ROC, 0.67 vs. 0.72, p= 0.017).
We additionally sought to evaluate how LPS and flagellin
performed in combination with antigen/antibody isotype
combinations selected, although responses to both antigens
are known to correlate. Here, as the responses were more
consistent in challenge study participants, only S. Typhi-specific
LPS was chosen for inclusion into multivariable modeling.
Frontiers in Microbiology | www.frontiersin.org 8 September 2017 | Volume 8 | Article 1794
fmicb-08-01794 September 14, 2017 Time: 16:28 # 9
Darton et al. Serodiagnostic Signatures of Typhoid Fever
FIGURE 6 | Multivariable analysis to find optimal antigen/antibody isotype signature. (A) Fold-change values of 12 target antigens plus flagellin and LPS in the
combined Oxford data. Antigens included in one of the final models are indicated by the colored squares below the antigens. (B) Risk scores for the Oxford samples
based on the antigens and coefficients in the four final models. (C) ROC curves for each of the final model based on the Oxford data comparing participants
diagnosed with typhoid fever (day 14 or TD96 h; brown) with those who stayed well (day 14; blue). (D) Fold-change values of 12 target antigens plus flagellin and LPS
in the Nepal data. Fold-changes were generated against the median of the healthy population (n = 50). Antigens included in one of the final models are indicated by
the colored squares below the antigens. (E) Risk scores for the Nepalese febrile control (orange) and typhoid (brown) samples based on the antigens and coefficients
in the final model. (F) External validation ROC curves for each of the final risk equation fitted to the Nepali data comparing febrile controls against typhoid cases.
We found LPS correlated with many of the other antigens
selected in our analyses and thus formed two models: with LPS
forced into the model (Model 3) and LPS alone (Model 4). The
signature suggested by model 3 also included IgG responses to
HlyE and IgA responses to cell invasion protein SipC (t2786).
SipC, together with SipB, forms the tip of the type-3 secretion
system (T3SS) encoded by SPI-1, and is involved in bacterial
pathogenesis and macrophage apoptosis, although is not specific
to S. Typhi (Nichols and Casanova, 2010; Kaur and Jain, 2012).
While all four signatures identified performed well when
reapplied to the CHIM datasets, final validation was performed
using samples gathered from a typhoid-endemic setting. Overall,
the reactivity in samples from the healthy control participants
was high, possibly reflecting environmental exposure of the
local population to Salmonella and other Gram-negative bacteria
(Pulickal et al., 2009). Application of the multivariable models not
containing LPS (Models 1 and 2) to the Nepal cohort produced
a moderate ability to discriminate febrile typhoid fever patients
from those with other causes of bacteremia, with the signature
containing IgM.t3090 performing significantly better. However,
the two LPS-containing signatures performed significantly better
again in this dataset. This is a similar finding to that by Davies
et al. (2016) in which the final selection of serodiagnostic antigens
in a Nigerian pediatric cohort included LPS and HlyE, and
IgA responses to LPS were mooted as being a useful indicator
of recent infection, albeit they were cross-reactive with NTS
sera.
In summary, these data offer an invaluable and unprecedented
insight into the dynamics of serological responses to acute
typhoid fever. Given the wide variety of settings in which
typhoid is still endemic, a signature composed of multiple
antigens remains likely to be the most universally useful approach
to the serodiagnosis of acute typhoid fever, both in endemic
settings and travelers returning from these settings. Specifically,
serodiagnostic responses in a new assay should include IgA
to S. Typhi LPS and IgG to HlyE, while several other novel
combinations merit assessment in further studies.
MATERIALS AND METHODS
Typhoid Controlled Human Infection
Models (CHIM)
Human challenge with S. Typhi was performed as previously
described (Darton et al., 2014, 2016; Waddington et al., 2014).
In brief, health adult male or female volunteers between 18
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TABLE 2 | Parameters of the four selected multivariable models.
Coefficient Standard error z-value p-value
Model 1
(Intercept) −1.8932 0.7273 −2.603 0.00924
IgM.t4398 −3.3309 1.4733 −2.261 0.02377
IgG.t0581 2.6645 1.2012 2.218 0.02655
IgM.t2002 2.3586 1.1021 2.14 0.03235
IgG.t1477 2.0183 0.779 2.591 0.00957
IgG.t1850 3.1504 1.0274 3.066 0.00217
Factor (Study T2) −1.0858 1.0249 −1.059 0.28942
Model 2
(Intercept) −1.3805 0.6681 −2.066 0.03879
IgM.t4398 −4.1001 1.6237 −2.525 0.01157
IgG.t0581 2.1095 0.9966 2.117 0.03429
IgG.t1477 2.4312 1.0371 2.344 0.01907
IgM.t3090 2.2378 1.1818 1.893 0.05829
IgG.t1850 3.4462 1.0828 3.183 0.00146
Factor (Study T2) −1.7175 1.0784 −1.593 0.11123
Model 3
(Intercept) −2.9124 1.0443 −2.789 0.00529
IgA.t2786 −2.4533 0.9472 −2.59 0.0096
IgG.t1477 1.957 0.9144 2.14 0.03234
StudyT2 −2.8085 1.6218 −1.732 0.08333
IgA_LPS 2.3243 0.6948 3.345 0.00082
Model 4
(Intercept) −1.9921 0.7006 −2.843 0.00446
IgA_LPS 1.5135 0.3565 4.245 2.18E-05
Factor (Study T2) −0.8241 0.9093 −0.906 0.36478
and 60 years of age were challenged with a single oral dose of
103−4 CFU S. Typhi (Quailes strain). Clinical data and samples
were collected prior to challenge (day 0 or ‘baseline’) and at
least daily for 14 days thereafter. In participants developing
persistent fever (oral temperature ≥38◦C for ≥12 h) and/or
with evidence of bacteremia (Gram-negative bacilli), a typhoid
diagnosis (TD) was made and antimicrobial treatment was
started (first-line: ciprofloxacin 500 mg twice-daily for 14 days;
Figures 1A,B). Diagnosed participants were seen at time points
after diagnosis to ensure resolution of clinical symptoms and for
collection of further sample material. All remaining participants
not diagnosed with typhoid by day 14 (nTD) were also
commenced on antimicrobial treatment. Further follow-up visits
into convalescence were performed 28, 60, and 90 days after
challenge and thereafter.
Two independent challenge cohorts were used in the present
study. The first study (discovery cohort; n = 41) consisted of
samples derived from a dose-escalation study performed in 2011
(Figure 1A) (Waddington et al., 2014). Serum samples were
collected 0 (pre-challenge baseline), 4, 7, 10, 14, 28, 60, and
90 days after S. Typhi ingestion in all participants, and at two
additional time points 48 h (TD48 h) and 96 h (TD96 h) after
TD (also referred to as ‘TD,’ n= 20).
The second study (validation cohort; n = 30) consisted of
samples collected from placebo-control arm participants taking
part in a randomized, double-blind, placebo-controlled vaccine
efficacy trial (Darton et al., 2016). Enrolment criteria and
endpoints in this study were identical to those in the initial-dose
escalation study; enrolment was completed between November
2011 and June 2012. Challenge and follow-up was performed
as described above (Figure 1B and Table 1); sera samples
were collected at days 0, 5, 10, 14, 28, 60, and 90 from all
participants and TD48 h and TD96 h in participants diagnosed
with typhoid.
Endemic Cohort
To validate the serodiagnostic signatures in a relevant patient
cohort, serum samples were gathered from three study cohorts
at Patan Hospital or the Civil Hospital both located in the
Lalitpur Sub-Metropolitan City area of Kathmandu Valley in
TABLE 3 | Comparison of receiver operator characteristic (ROC) curves in Nepal
data.
ROC model 1 ROC model 2 p-value1
0.6706 0.715 1.77E-02
ROC model 1 ROC model 3 p-value
0.6706 0.8736 8.83E-06
ROC model 1 ROC model 4 p-value
0.6706 0.8805 6.29E-06
1DeLong’s test for two correlating ROC curves.
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Nepal. Firstly, plasma samples were collected from febrile
patients presenting to hospital and diagnosed with blood culture-
confirmed S. Typhi infection (n = 100; Figure 1C and Table 1).
Samples were collected from patients enrolled into a parent
treatment comparison study (Arjyal et al., 2016), or if ineligible,
into a diagnostics sub-study; samples from healthy control
volunteers were also collected as part of this sub-study. Finally,
plasma samples were collected from patients presenting with
fever and a laboratory confirmed of non-typhoid bacteremia
(n= 52).
Ethics Statement
All trials were conducted in accordance with the relevant clinical
trial protocols, the principles of the Declaration of Helsinki, and
the International Conference on Harmonization (ICH) Good
Clinical Practice standards. Ethical approval for the Oxford
CHIM studies was provided by the United Kingdom National
Research Ethics Service (Oxford Research Ethics Committee
A, 10/H0604/53 and 11/SC/0302) (Waddington et al., 2014;
Darton et al., 2016). Both studies were performed by the
University of Oxford at the Centre for Clinical Vaccinology
and Tropical Medicine, Oxford, and monitored by the Clinical
Trial Research Governance department of the University of
Oxford.
The parent treatment trial and diagnostics sub-study
performed in Nepal were given ethical approval by the Oxford
Tropical Ethics Committee (OxTREC, ref. 38–11) and the
Nepal Health Research Council (ref. 03NP). The trial was
performed by the Oxford University Clinical Research Unit,
Nepal supported and monitored by OUCRU, Vietnam. All
study participants (or their parents if aged under 18 years in
Nepal) provided written informed consent prior to enrolment.
Illiterate signatories in Nepal, were read details of the consent
form in the presence of a literate witness, who could attest
to the accurate reading of the consent and agreement of the
signatory.
Sample Collection
Venous blood was collected from participants, and for the
purposes described here, sera (Oxford studies) or plasma (Nepal
cohort) was separated by centrifugation from clotted blood
and stored at −70◦C prior to separation and shipment for
assays.
Array Design
A full array of 4445 target S. Typhi antigens was used to assess
sera from the discovery set. Antigen targets were expressed using
a coupled in vitro transcription and translation (IVTT) system,
E. coli based cell-free Rapid Translation System (RTS) 100 High
Yield Kit (5 Prime). Approximately 1 nL of unpurified IVTT
reactions were spotted onto nitrocellulose coated Oncyte Avid
Slides (Grace Bio-Labs) using an OmniGrid Accent microarray
printer (Digilab). Each array also contained 192 positive control
spots (human IgG, IgM, IgA and anti-human IgG, IgM, IgA)
and 227 negative IVTT control spots, consisting of spotted IVTT
reactions with no S. Typhi plasmid added. A down-selected
array was designed containing 223 S. Typhi, 6 dengue virus,
11 P. falciparum antigens, S. Typhi Vi-polysaccharide (‘Vaccine’;
Sanofi Pasteur, Maidenhead, United Kingdom) and purified S.
Typhi flagellin (‘H’; prepared by isolation from S. Typhi Quailes
strain and purification at the University of Maryland School of
Medicine) and lipopolysaccharide (LPS or ‘O,’ S. Typhosa L2387;
Sigma–Aldrich, Dorset, United Kingdom) (Supplementary Table
S2). The down-selected array was probed in duplicate for each
participant sample.
Sample Probing
Serum samples were diluted 1:100 in a 3 mg/mL E. coli
DH5α lysate solution in protein arraying buffer and incubated
at room temperature for 30 min. Chips, FAST Slide Holders
and FAST Slide Incubation Chambers were assembled and
nitrocellulose pads were hydrated using 100 µL blocking
buffer for 30 min at room temperature with rocking. Blocking
buffer was removed, pre-incubated samples were added and
chips were incubated overnight at 4◦C with agitation. The
following day, chips were washed three times with 1x TBS-
0.05% Tween 20, followed by incubation with biotin-conjugated
anti-human secondary antibodies against the target antibody
isotype (IgG, IgA or IgM; Sigma–Aldrich) diluted 1:1000 in
blocking buffer for 1 h at room temperature with agitation.
Chips were washed three times with 1x TBS-0.05% Tween 20,
followed by incubation with streptavidin-conjugated SureLight
P-3 (Columbia Biosciences) at room temperature protected from
light with agitation. Chips were washed three times with 1X
TBS-0.05% Tween 20, three times with 1X TBS, and once with
water. Chips were air dried by centrifugation at 500 × g for
10 min, stored in a light -proof desiccator for >2 h before
scanning.
Raw Data Processing
After probing, arrays were scanned using a GenePix 4300 scanner
to acquire fluorescent intensity (FI) values for each spot on
the array. Raw intensity values were determined by subtracting
background FI (immediate surrounding area of a given spot)
from foreground FI (spot intensity).
Data Normalization
The raw signal was normalized by dividing the IVTT protein
spot intensity by the sample specific median of the IVTT
control spots printed throughout the chip and taking the base-
2 logarithm of the ratio. The normalized data provide a relative
measure of the specific antibody binding to the non-specific
antibody binding to the IVTT control spots. With the normalized
data, a value of 0.0 means the intensity is no different than
background and a value of 1.0 indicates a doubling with respect
to background.
Initial Data Analysis
Overall reactivity of discovery set sera collected up to day
28 after challenge was visualized using the median raw FI of
each antibody isotype (IgA, IgG, and IgM) to each antigen
assayed (Supplementary Figure S1). Setting an arbitrary cut-
off of 5,000 mfi, some reactivity was seen in IgA responses
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(to 6 antigens), while a broader range of reactivity was seen
by IgM and IgG isotypes (both to 26 antigens). To compare
evolution of the antibody responses from the period of S. Typhi
ingestion into convalescence (day 28) between TD participants
and those not diagnosed after challenge (also referred to as
‘nTD’), we determined the number of reactive antigens (fold-
change over baseline threshold of >1.5 in >2 participants) at
each time point (mean number of reactive antigens/participant;
Figure 2A).
Selection of Seroreactive Antigens
The reactivity of each antigen/antibody isotype combination
for each participant was assessed at the day 14 time point
in all participants plus the TD96 h time point in TD
participants, according to the outcome after challenge. The
TD96 h time point was included as, although challenge study
participants were treated at the earliest opportunity after the
study definitions for diagnosis had been reached, the WHO
clinical case definition of typhoid requires at least 3 days
of symptomatic/febrile illness (World Health Organisation,
2003). Classification as to whether each antigen was reactive
or not required a 1.5-fold increase in normalized FI over
individual baseline measurement. Antigen/antibody isotype
combinations were selected for further investigation if reactivity
was seen in 3 or more TD participants at either time
point.
To assess reactivity in the validation set of those target
antigens and antibody isotypes identified in the discovery set,
we compared the log2 fold-change in FI reactivity between the
TD96 h or day 14 time point and corresponding individual
baseline values.
Feature Selection Using Machine
Learning Algorithms
Fold-change values (log2 over baseline) were created for all
participants in the Oxford datasets. As the validation set was
probed in duplicate, the mean FI value for each pair was
used unless one spot was not above background in which
case a single value was used; to avoid artificially increasing
fold-change values, we set the time point log2 fold-change
to zero as soon as one value was below the lower limit of
detection. To select features for building a multivariable model,
we combined the discovery and validation set into one large
data matrix (superset). To assess algorithm performance, we
created 500 training and test set partitions from the superset
using random sampling with replacement (bootstrapping). For
each training iteration we used internal feature importance
measures to rank each feature and selected the top 20 features
for further assessment. In a stepwise approach, we re-trained
the training set on the top 2 to top 20 features and recorded
the cross-validation accuracy. Where the accuracy was highest,
these features were taken forward as classifier and used
to predict the test set and balanced accuracy and AUROC
values recorded as performance measures (see Supplementary
Methods).
Statistical Analysis
Statistical analysis was performed in R version 3.3.1 (2016-
06-21). Differences in normalized log2 FI between baseline
(pre-challenge) values and subsequent time point values were
determined by paired t-tests. To identify a combination of a
small number of antigen/antibody isotypes which were most
predictive of typhoid challenge outcomes (TD or nTD) in
a multivariable framework, we performed subset selection
of multivariable logistic regression. The outcome in the
model was the binary classification of typhoid diagnosis
(TD = 1; nTD = 0) and the independent variables were the
antigens and an indicator variable to account for the batch
effect of having data from two different challenge studies
(study= T1/T2).
Many of the 35 candidate antigen/antibody isotype
combinations identified in the PLS machine learning approach
were highly correlated with each other therefore unable to be
included in a multivariable model together. The 35 candidate
antigen/antibody isotypes were reduced prior to model fitting
by removing those antigen/isotype combinations with the
lowest frequency of selection (<30%) and those combinations
which consisted of two isotypes of the same antigen and were
therefore highly correlated (correlation cut-off rho > 0.7). This
reduction in variables was conducted to overcome two potential
problems: model overfitting and model non-convergence.
Model overfitting occurs when fitting models with a large
number of predictor variables to a relatively small dataset and
results in models which do not perform well when validated
on external datasets. Model non-convergence occurs when
coefficients and their standard errors cannot be computed,
or are exceedingly large, due to multicollinearity in the
data.
The final list of candidate variable included 12 candidate
antigen/antibody isotype variables. Variable subset selection
using logistic regression was performed on these 12 variables
using back and forward step-wise feature selection with the
‘stepAIC’ function in R ‘MASS’ package (Venables and Ripley,
2002), to select the optimal combination. Non-significant
variables were excluded from the model resulting in a final
model consisting of a five significant antigen/antibody isotype
combination. Individual risk scores were calculated from the
linear predictor (risk equation) of the logistic regression, i.e.,
the sum of the fold-change values multiplied by variable
coefficients for each participant. Risk equations were applied to
the Nepal dataset as an external validation, and the AUC ROC
computed.
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